Partnered with SRx Health Solutions and BioScript Solutions to Build Out a Network of NeonMind-branded Specialty Mental Health Clinics Across Canada OAKVILLE, ON / ACCESSWIRE / April 12, 2022 / NeonMind...
Announced today plans to launch 10 specialty mental health clinics over the next 3 years through alliances ...
Announced today it is setting up to offer low dose intravenous ketamine therapy for mood and anxiety ...
Psychedelics could soon revolutionize the $2.5 trillion mental health market. In fact, according to co-CEO of the ATMA Journey Centers, David Harder, a quoted in a company press release, “The surge...
Announced today it has released preclinical data demonstrating the efficacy of psilocybin in reducing ...
The world may be a step closer to successfully treating obesity with psilocybin. That's because psilocybin activates serotonin receptors, or "nature's own appetite suppressant," as noted by Psychology...
Announces today it has filed a new patent application with the United States Patent and Trademark Office ...
NeonMind Biosciences (CSE: NEON) (OTC: NMDBF) is another step closer to treating the global obesity epidemic. At the moment, worldwide obesity has tripled since 1975, says the World Health Organization....
Provided a summary of business highlights on the Company's activities and progress across its Pharmaceutical ...
NeonMind Biosciences (CSE:NEON)(OTC:NMDBF) is a step closer to bringing innovative psychedelic-based treatments to people suffering from obesity and mental health disorders. With obesity, for example,...